KR20080026084A - Gastrointestinal drug composition - Google Patents
Gastrointestinal drug composition Download PDFInfo
- Publication number
- KR20080026084A KR20080026084A KR1020077022751A KR20077022751A KR20080026084A KR 20080026084 A KR20080026084 A KR 20080026084A KR 1020077022751 A KR1020077022751 A KR 1020077022751A KR 20077022751 A KR20077022751 A KR 20077022751A KR 20080026084 A KR20080026084 A KR 20080026084A
- Authority
- KR
- South Korea
- Prior art keywords
- gastrointestinal
- nausea
- mmsc
- stomach
- vomiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Description
본 발명은 메틸메티오닌설포늄클로라이드(MMSC) 및 창출을 함유하는 효력이 현저하게 증강된 위장약 조성물에 관한 것이다.The present invention relates to gastrointestinal drug compositions with markedly enhanced potency containing methylmethioninesulfonium chloride (MMSC) and production.
일반적으로 위장약이란 과식, 가슴앓이, 체증, 위통, 구역질, 구토 등의 증상을 완화하는 작용을 나타내어, 위장을 건강한 상태로 유지하는 혹은 건강한 상태로 회복시키기 위해서 널리 이용되고 있는 의약으로, 소화제, 건위약, 제산약, 복합 위장약, 위장 진통 진경약 등으로 세분류된다.In general, gastrointestinal drugs are used to alleviate symptoms such as overeating, heartburn, congestion, stomach pain, nausea and vomiting, and are widely used to keep the stomach in a healthy state or to restore a healthy state. Placebo, antacid, complex gastrointestinal, gastrointestinal analgesic, etc.
메틸메티오닌설포늄클로라이드(MMSC)는 손상된 위점막을 수복하는 작용을 가지기 때문에, 위장약, 특히 복합 위장약의 1 성분으로 널리 이용되고 있다. 또 창출(蒼朮)은 모창출(茅蒼朮, Atractylodes lancea De Candolle) 또는 북창출(北蒼朮, Atractylodes chinensis Koidzumi)의 근경으로, 예로부터 생약으로 인지되어, 주로 건위 소화제나 지사 정장약 등으로 이용되어 왔다 (비특허문헌 1). 그러나, 양자를 배합한 의약 조성물, 특히 위장약은 지금까지는 존재하지 않고 있다.Since methylmethioninesulfonium chloride (MMSC) has an effect of repairing a damaged gastric mucosa, it is widely used as one component of gastrointestinal drugs, especially complex gastrointestinal drugs. Creation can be either Atractylodes lancea De Candolle or Atractylodes chinensis Koidzumi ) has been recognized as a herbal medicine since ancient times, and has been mainly used as a dry stomach extinguishing agent, a branch medicine or the like (Non-Patent Document 1). However, the pharmaceutical composition which mix | blended both, especially gastrointestinal agent does not exist until now.
[비특허문헌 1] 제14개정 일본약전해설서, 2001년, D-674∼677쪽[Non-Patent Document 1] The 14th Amendment to Japan Pharmacopoeia, 2001, pp. D-674-677
발명이 해결하려고 하는 과제Challenges the invention seeks to solve
본 발명의 목적은 종래의 위장약에 비해서 유효성이 현저하게 높아진 새로운 위장약 조성물을 제공하는 것이다.It is an object of the present invention to provide a new gastrointestinal composition which is significantly higher in effectiveness compared to conventional gastrointestinal drugs.
과제를 해결하기 위한 수단Means to solve the problem
본 발명자들은 위점막 수복제로서 알려진 메틸메티오닌설포늄클로라이드(MMSC)와, 건위 소화제 혹은 지사 정장약으로서 알려져 있는 창출를 조합시켜서 사용하면, 현저한 소화관의 운동 부활화 작용을 나타내고, 그 결과, 트림, 구역질, 오심 혹은 구토의 억제, 또는 조기 포만감, 체증, 소화불량, 위부ㆍ복부팽만감 혹은 식욕부진의 해소 등의 위장약으로서의 효과가 비약적으로 높아지는 것을 발견하고, 본 발명을 완성하였다.When the present inventors use a combination of methylmethioninesulfonium chloride (MMSC) known as gastric mucosal repair agent and a production known as a gastric digestive or branch office dressing agent, the present inventors show a significant activating action of the digestive tract, resulting in trimming and nausea. The present invention has been found to dramatically increase the effect as a gastrointestinal drug such as suppression of nausea or vomiting, or early satiety, weight, indigestion, stomach and abdominal bloating or anorexia.
즉, 본 발명은, MMSC 및 창출을 함유하는 위장약 조성물을 제공한다. 또 본 발명은 트림, 구역질, 오심 혹은 구토의 억제, 또는 조기 포만감, 체증, 소화불량, 위부ㆍ복부팽만감 혹은 식욕부진의 해소를 위한 MMSC 및 창출을 함유하는 위장약 조성물에 관한 것이다.That is, the present invention provides a gastrointestinal drug composition containing MMSC and production. The present invention also relates to a gastrointestinal drug composition containing MMSC and creation for suppressing burping, nausea, nausea or vomiting, or for relieving premature satiety, congestion, indigestion, stomach, abdominal bloating or anorexia.
발명의 효과Effects of the Invention
본 발명인 위장약 조성물은 MMSC 혹은 창출을 각각 단독으로 사용하여도 얻을 수 없는 상승적으로 높아진 소화관의 운동 부활화 작용에 의해, MMSC가 가지고 있는 트림, 구역질, 오심 혹은 구토의 억제, 또는 조기 포만감, 체증, 소화불량, 위부ㆍ복부팽만감 혹은 식욕부진의 해소 등의 효과가 현저하게 높일 수 있다는 효과를 얻을 수 있다.The gastrointestinal medicinal composition of the present invention has the effect of activating the synergistically elevated digestive tract, which cannot be obtained by using MMSC or production alone, respectively, to suppress the trimming, nausea, nausea or vomiting of MMSC, or premature satiety, congestion, The effect of relieving indigestion, stomach and bloating or loss of appetite can be significantly increased.
발명을 실시하기Implement the invention 위한 최선의 형태 Best form for
MMSC는 1959년에 판매가 시작된 의약으로, 주로 위점막 수복제로서, 혹은 만성 간질병에 있어서의 간기능의 개선을 위해서 사용되어 왔다. 그러나, MMSC와 창출이 병용해서 사용되는 것에 의해서 현저한 소화관의 운동 부활화 작용을 나타내고, 그 결과, 트림, 구역질, 오심 혹은 구토의 억제 효과, 또는 조기 포만감, 체증, 소화불량, 위부ㆍ복부팽만감 혹은 식욕부진의 해소 효과가, MMSC를 단독으로 사용하였을 경우와 비교해서 현저하게 높일 수 있는 것에 대해서는 지금까지는 보고도 시사도 없다.MMSC is a drug launched in 1959 and has been used primarily as a gastric mucosal repair or for improving liver function in chronic epilepsy. However, the use of MMSC and creation in combination shows a marked reactivation of the movement of the digestive tract, resulting in a suppressive effect of belching, nausea, nausea or vomiting, or premature satiety, congestion, indigestion, stomach and abdominal bloating or There has been no report or suggestion so far that the effect of relieving anorexia can be remarkably improved as compared with the case of using MMSC alone.
또, 창출에 대해서도 소화관의 운동을 항진시키는 기능은 알려져 있었 (비특허문헌 1)지만, MMSC와의 병용에 의해서 이러한 기능이 상승적으로 증강되고, 그 결과, MMSC와 창출을 함유하는 위장약 조성물로서의 효과가 상승적으로 높아지는 것에 대해서는, 지금까지는 보고도 시사도 없다.Moreover, although the function which promotes the exercise of the digestive tract is known also about creation (nonpatent literature 1), these functions are synergistically augmented by use with MMSC, As a result, the effect as a gastrointestinal composition containing MMSC and creation is There is neither report nor suggestion so far about rising synergistically.
본 발명은 종래 조합되어 사용된 적이 없었던 MMSC와 창출과의 병용에 의해, 각각 단독의 사용에서는 달성되지 않는 상승적으로 높아진 효과를 가지는 위장약 조성물을 제공하는 것이다.The present invention provides a gastrointestinal medicinal composition having a synergistically increased effect, which is not achieved by use alone, by combination with MMSC and creation, which have never been used in combination before.
본 발명의 위장약 조성물은 후술하는 실시예에서 나타내는 바와 같이, 장관 수송율로 나타나는 소화관의 운동을 부활화시키는 작용을 가지고 있다. 그 효과는 MMSC, 창출 각각 단독으로 사용하였을 때에 인정되는 효과의 합산보다도 유의하게 높아, 상승적으로 작용해서 소화관의 운동을 부활화 시키고 있음이 인정된다.The gastrointestinal medicinal composition of the present invention has an action of activating the movement of the digestive tract represented by the intestinal transport rate, as shown in Examples described later. It is recognized that the effect is significantly higher than the sum of the effects recognized when each of MMSC and generation alone is used, and it is synergistically activated to revitalize the digestive tract.
이하의 추론에 구속되는 것은 아니지만, 본 발명에 있어서는, 이러한 소화관 운동의 상승적인 부활화에 의해, 장관 내용물의 체류를 원인으로 하는 트림, 구역질, 구토, 조기 포만감, 체증, 소화불량, 위부ㆍ복부팽만감 및 식욕부진 등의 증상, 특히 과음 혹은 과식에 의해 발생하는 이것들의 증상이, MMSC 혹은 창출을 단독으로 사용하는 경우와 비교해서, 현저하게 개선되는 것으로 추측된다. 또, 소화관 운동의 상승적인 부활화에 의해, 장관 내용물의 체류가 해소되어, 소화촉진을 보다 강하게 촉진시킬 수도 있다. Although not limited to the following inferences, in the present invention, by synergistic revitalization of the gastrointestinal tract movement, belching, nausea, vomiting, premature satiety, congestion, indigestion, stomach and abdomen caused by retention of intestinal contents Symptoms such as bloating and loss of appetite, especially those caused by excessive drinking or overeating, are thought to be remarkably improved compared to the case of using MMSC or production alone. In addition, the synergistic revitalization of the digestive tract movement relieves retention of the intestinal contents, thereby facilitating digestion promotion more strongly.
본 발명에서 사용하는 MMSC는 예를 들면 요네자와하마리약품공업(주)에서 시판되고 있는 것을 사용할 수도 있고, 또 일본 특허공보 S36-13209호에 기재된 방법에 따라서 합성하여 사용할 수도 있다. 또 창출에 대해서도, 생약성분으로 널리 유통되어 사용되고 있는 것을 입수하여 사용할 수도 있다. MMSC used by this invention can use what is marketed by Yonezawa Hamari Pharmaceutical Co., Ltd., for example, can also be synthesize | combined according to the method of Unexamined-Japanese-Patent No. S36-13209. Moreover, also about creation, you can obtain and use what is widely distributed and used as a herbal ingredient.
MMSC와 창출의 배합비와 이것들의 상승작용에 대해서는, 중량비로 MMSC: 창출(원생약 환산)이 9부: 8부∼3부: 500부, 특히 1부: 2부∼1부: 5부일 경우에 있어서, 병용에 의한 상승적인 효과를 특히 강하게 발휘시킬 수 있다. 또 MMSC와 창출의 조성물 중의 배합량은 각각 위장약 조성물로서 배합 가능한 량의 범위로부터, 상기의 배합비를 만족시키는 량을 각각 결정해서 사용할 수 있다. For the compounding ratio of MMSC and creation and their synergy, the weight ratio of MMSC: Creation (raw drug equivalent) is 9 parts: 8 parts-3 parts: 500 parts, especially 1 part: 2 parts-1 part: 5 parts Therefore, the synergistic effect by combined use can be exhibited particularly strongly. Moreover, the compounding quantity in MMSC and the composition of creation can respectively determine the quantity which satisfy | fills said compounding ratio from the range of the amount which can be mix | blended as a gastrointestinal drug composition, and can use.
또, 본 발명의 위장약 조성물은 MMSC와 창출의 이외에, 의약상 허용되는 담체나 다른 의약성분, 부형제, 결합제, 붕해제, 활택제, 착색제, 교미제등 을 함유하는 의약조성물의 형태로서도 사용할 수 있다.The gastrointestinal composition of the present invention can also be used in the form of a pharmaceutical composition containing a pharmaceutically acceptable carrier, other pharmaceutical ingredients, excipients, binders, disintegrants, lubricants, coloring agents, copulation agents, etc., in addition to MMSC and creation. .
부형제로서는 락토스, 전분류, 결정 셀룰로오스, 슈크로스, 만니톨, 경질무수 규산 등을 들 수 있다. 결합제로서는 하이드록시프로필메틸셀룰로즈, 하이드록시프로필셀룰로즈, 젤라틴, 알파화 전분, 폴리비닐피롤리돈, 폴리비닐알코올, 풀루란 등을 들 수 있다. 붕해제로서는 카멜로오스, 카멜로오스칼슘, 크로스카멜로오스나트물, 크로스포비돈, 옥수수 전분, 저치환도 하이드록시프로필셀룰로즈 등을 들 수 있다. 활택제로서는 스테아린산마그네슘, 탈크 등을 들 수 있다. 착색제로서는 타르 색소, 삼이산화철 등을 들 수 있다. 교미제로서는 스테비어, 아스파르탐, 향료 등을 들 수 있다.Examples of the excipient include lactose, starch, crystalline cellulose, sucrose, mannitol, hard anhydrous silicic acid, and the like. Examples of the binder include hydroxypropyl methyl cellulose, hydroxypropyl cellulose, gelatin, alpha starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan and the like. Examples of the disintegrant include cameloose, cameloose calcium, croscarmellose, crospovidone, corn starch, low-substituted hydroxypropyl cellulose and the like. Examples of the lubricants include magnesium stearate and talc. As a coloring agent, a tar pigment | dye, iron trioxide, etc. are mentioned. Examples of the mating agent include stevia, aspartame, fragrance, and the like.
본 발명의 위장약 조성물은 목적에 따라서, 분말제, 과립제, 정제, 츄어블 정, 필름 코팅정, 당의정, 드링크제, 연캡슐제, 경캡슐제, 젤리제 등의 제형으로 제조해서 사용 할 수 있다. 특히, 분말제, 과립제, 정제, 필름 코팅정의 제형으로 제조해서 사용하는 것이 바람직하다.The gastrointestinal composition of the present invention can be prepared and used in the form of powders, granules, tablets, chewable tablets, film coated tablets, dragees, drinks, soft capsules, light capsules, jellys and the like according to the purpose. In particular, it is preferable to manufacture and use in the form of powder, a granule, a tablet, and a film-coated tablet.
또, MMSC 및 창출을 함유하는 위장약 조성물의 인간에 대한 투여량으로서는, 제형, 질병의 정도, 환자의 연령 등의 요소에 의존하지만, 보통 성인에 대하여 MMSC를 기본으로 30∼3000 mg/일 정도, 특히 100∼225 mg/일 정도를 투여할 수 있고, 이러한 투여량에 맞추어서 창출의 투여량을 결정할 수 있다.In addition, the dosage of the gastrointestinal drug composition containing MMSC and the production to human depends on factors such as the dosage form, the severity of the disease, the age of the patient, etc., but about 30 to 3000 mg / day based on the MMSC for adults, In particular, about 100 to 225 mg / day may be administered, and the dosage of production may be determined according to such dosage.
이하에, 실시예를 이용해서 본 발명을 구체적으로 설명하지만, 본 발명은 이것들에 한정되는 것은 아니다.Although an Example demonstrates this invention concretely below, this invention is not limited to these.
실시예 1Example 1
시험 전일에 절식한 5주령의 ddy계 웅성 마우스에, 0.5% 메틸셀룰로오스(이하, ‘ＭＣ’라고 한다.)에 현탁시킨 메틸메티오닌설포늄클로라이드(1000 mg/kg, 이하, ‘M’라고 한다.), 창출 건조엑스S(300 mg/kg, 원생약 환산량으로 3000 mg/kg. 이하, ‘S’라고 한다.) 및 그것들의 혼합물(이하’M+S’라고 한다)을 경구투여 하고, 그 15분 후에 활성탄소 분말 현탁액을 경구투여하였다. 또, 그 30분 후에 동물을 경추탈구하여 죽이고, 유문부에서 회맹부까지의 장관을 적출하였다. 피험물질의 장관수송능은 유문부에서의 탄소분말의 이동거리를 장관의 전체길이로 나누고, 장관 수송율로 나타냈다.Methyl methionine sulfonium chloride (1000 mg / kg, hereinafter referred to as 'M') suspended in 0.5% methyl cellulose (hereinafter referred to as 'MC') in 5-week-old ddy male mice fasted the day before the test. ), Dry dry S (300 mg / kg, 3,000 mg / kg or less in terms of protozoa), or a mixture thereof (hereinafter referred to as 'M + S'), orally After 15 minutes, the activated carbon powder suspension was orally administered. After 30 minutes, the animal was cervically dislocated and killed, and the intestine from the pyloric to the parliament was removed. The intestinal transport capacity of the test substance was divided by the total length of the intestine, divided by the total length of the intestine, and expressed as the intestinal transport rate.
시험 결과를 표 1에 나타낸다.The test results are shown in Table 1.
장관 수송율은 ＭＣ를 컨트롤에서 48.5%, M그룹에서 69.0%, S그룹에서 53.0%, M+S그룹에서 76.2%이었다. 컨트롤의 장관 수송율을 1로 하였을 때의 Ｍ+S그룹의 장관 수송율의 비율은 1.57이며, 단미(單味)그룹의 곱의 1.55(1.42×1.09)에 비해서 크고, 상승효과가 있음으로 판정되었다. 이것으로, 본 발명이 소화관 운동기능을 촉진하고, 그 결과, 트림, 구역질, 오심 혹은 구토의 억제, 또는 조기 포만감, 체증, 소화불량, 위부ㆍ복부팽만감 혹은 식욕부진의 해소 등에 있어서 현저하게 증강된 위장약 조성물로서 매우 유용하다는 것이 분명하게 되었다. The intestinal transport rate was 48.5% in the MC, 69.0% in the M group, 53.0% in the S group and 76.2% in the M + S group. The ratio of the intestinal transport rate of the M + S group when the intestinal transport rate of the control is set to 1 is 1.57, which is larger than that of 1.55 (1.42 × 1.09) of the product of the single group, which is judged to have a synergistic effect. It became. As a result, the present invention promotes the functioning of the digestive tract, and as a result, is significantly enhanced in suppressing burping, nausea, nausea or vomiting, or relieving premature satiety, congestion, indigestion, stomach and bloating or loss of appetite. It has become clear that it is very useful as a gastrointestinal drug composition.
실시예 2Example 2
부형제로서 락토스를 이용하고, 통상의 방법의 습식 과립법에 의해 MMSC를 함유하는 과립을 과립한 후, 통상의 방법에 의해 압축 성형하여 1정당 25 mg의 MMSC를 함유하는 정제A를 제조하였다. 또, 같은 방법으로 1정당 25 mg의 MMSC 및 12 mg (원생약 환산)의 창출을 함유하는 정제 B를 제조하였다.Tablet A containing 25 mg of MMSC per tablet was prepared by granulating granules containing MMSC by the conventional method of wet granulation using lactose as an excipient, followed by compression molding by the conventional method. In the same manner, Tablet B containing 25 mg of MMSC and 12 mg (prototype equivalent) per tablet was prepared.
위(胃)에 대해서 일정한 복부 부정수소를 호소하는 20∼50대의 자원봉사자 남성 10명을 무작위로 선발하고, 5명씩 2그룹(A그룹 및 B그룹)으로 나누었다. A그룹에 대해서는 정제 A를, B그룹에는 정제 B를, 각각 3일간 연속하여 매 식사 후 2정씩을 복용시켰을 때의, 복용 전ㆍ중ㆍ후에 있어서의 부정수소의 증상의 추이를 앙케이트 형식으로 회답하게 하였다. 그 결과를 표 2에 나타낸다.Ten male volunteers in their twenties and fifties who complained of constant abdominal hydrogen were randomly selected and divided into two groups (Group A and Group B). Regarding group A, tablet B was given to group B, and tablet B was given for two consecutive days after each meal for three consecutive days. It was made. The results are shown in Table 2.
표 2에서 분명하게 알 수 있는 바와 같이, 본 발명의 위장약 조성물을 복용한 B 그룹에 있어서, 복부 부정수소의 증상의 현저한 개선 효과가 확인되었다.As can be clearly seen in Table 2, in the group B in which the gastrointestinal drug composition of the present invention was taken, a marked improvement in the symptoms of abdominal hydrogen was confirmed.
Claims (5)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005156667 | 2005-05-30 | ||
| JPJP-P-2005-00156667 | 2005-05-30 | ||
| PCT/JP2006/309791 WO2006129479A1 (en) | 2005-05-30 | 2006-05-17 | Gastrointestinal drug composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20080026084A true KR20080026084A (en) | 2008-03-24 |
| KR101254511B1 KR101254511B1 (en) | 2013-04-19 |
Family
ID=37481410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020077022751A KR101254511B1 (en) | 2005-05-30 | 2006-05-17 | Gastrointestinal drug composition |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP5070047B2 (en) |
| KR (1) | KR101254511B1 (en) |
| CN (1) | CN101141972A (en) |
| TW (1) | TWI430807B (en) |
| WO (1) | WO2006129479A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013089383A1 (en) * | 2011-12-13 | 2013-06-20 | 에스케이케미칼 주식회사 | Compound effective for preventing or treating irritable bowel syndrome, and composition containing same |
| KR101399513B1 (en) * | 2009-05-22 | 2014-05-28 | 에스케이케미칼주식회사 | Composition for preventing or treating irritable bowel syndrome |
-
2006
- 2006-05-05 TW TW095116012A patent/TWI430807B/en active
- 2006-05-17 JP JP2007518901A patent/JP5070047B2/en active Active
- 2006-05-17 CN CNA2006800087386A patent/CN101141972A/en active Pending
- 2006-05-17 KR KR1020077022751A patent/KR101254511B1/en active IP Right Grant
- 2006-05-17 WO PCT/JP2006/309791 patent/WO2006129479A1/en active Application Filing
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101399513B1 (en) * | 2009-05-22 | 2014-05-28 | 에스케이케미칼주식회사 | Composition for preventing or treating irritable bowel syndrome |
| WO2013089383A1 (en) * | 2011-12-13 | 2013-06-20 | 에스케이케미칼 주식회사 | Compound effective for preventing or treating irritable bowel syndrome, and composition containing same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101254511B1 (en) | 2013-04-19 |
| WO2006129479A1 (en) | 2006-12-07 |
| JP5070047B2 (en) | 2012-11-07 |
| TW200716160A (en) | 2007-05-01 |
| CN101141972A (en) | 2008-03-12 |
| JPWO2006129479A1 (en) | 2008-12-25 |
| TWI430807B (en) | 2014-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH06502194A (en) | Rapidly disintegrating multiparticulate tablet | |
| CN102526058A (en) | Anti-inflammatory analgesic medicinal composition containing lornoxicam and esomeprazole | |
| CN101647805B (en) | Glucosamine chewable tablet used for relieving and preventing osteoarthritis and preparation method thereof | |
| JP2002531491A (en) | Sustained-release tablet containing hydrocolloid and cellulose ether | |
| CN101277721B (en) | Orally disintegrating tablet | |
| JP2007169247A (en) | Ginger-containing oral composition | |
| JP2010030963A (en) | Gastrointestinal tract movement activation regulator | |
| JP2008056567A (en) | Medicine for treatment or prevention of gastrointestinal disease | |
| KR101254511B1 (en) | Gastrointestinal drug composition | |
| JP6864970B2 (en) | Gastrointestinal drug composition | |
| JP2006514041A (en) | Composition for suppressing obesity using mixed herbal materials | |
| JPH04193823A (en) | Pill readily crushable with teeth and easily administrable without water | |
| JPH0491029A (en) | Galenical drug blended chewable tablet | |
| JP3982889B2 (en) | Pharmaceutical preparations containing ibuprofen | |
| JPH0656677A (en) | Antacid composition | |
| KR102431738B1 (en) | Very rapidly disintegrating tablet, and method for producing same | |
| KR20080003318A (en) | Gastrointestinal motor activation regulator | |
| KR101779513B1 (en) | Pharmaceutical composition comprising the isopropanol extract of artemisia | |
| CN102210681B (en) | Application of ectoine and derivatives thereof in preparing medicament for treating digestive tract diseases | |
| KR20040047588A (en) | Medicinal compositions | |
| CA2639895A1 (en) | Energizing compositions comprising goji, red clover and polygonum multiflorum, and uses thereof | |
| CN1078468C (en) | Health-care products composition | |
| KR102482128B1 (en) | Compositions containing new methylsulfonylmethane(MSM) with increased arthritis treatment effect and the process of manufacture thereof | |
| JP2003095981A (en) | Medicine composition | |
| CN1220508C (en) | Medicine for curing diseases of digestive system and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20160318 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20170317 Year of fee payment: 5 |